Products and services

Scope

RD Saúde’s role as an innovation platform that creates business models to take care of the population’s health, promoting products with sustainability attributes and developing their value chain, considering the expansion of private label portfolios.

Impact Sphere

Employees, contractors, suppliers, customers

Disclosures

GRI 416: Customer Health and Safety

Sustainable Development Goals

Theme management

2025 Strategy

Over the past four years, we have focused our business strategy to revitalize the role of the pharmacy beyond retail, delivering health care to the population by redefining its potential and expanding the range of integral health care services. Through this journey, we intend to build a new primary care model supported by two pillars: New Pharmacy and health Care Platform.

(inserir imagem da página 48 do Relatório)

New Pharmacy is one of the pillars of our 2025 Strategy, through which we have evolved to turn pharmacies into integral health hubs, expanding our presence in the customers’ health journey.

The development of the health Care Platform marks a continuation of New Pharmacy. By expanding our primary health care actions with a greater range of services, we are reinforcing our bond with customers and establishing a stronger presence throughout their health care journey.

Learn more about the 2025 Strategy here. (link para um PDF sobre a Estratégia)

Private Label Products

The development process for private label products is carried out through strategic industry partnerships, which undergo a thorough qualification and risk assessment process. We identify and seek to expand our partnerships with suppliers, always aligned with the best social and environmental practices. Through the Supplier ESG Management Policy, we ensure that our partners meet the highest standards of quality and responsibility.

* Quality Deviations: If quality deviations are identified, we initiate an investigation with the supplier and, if a manufacturing error is confirmed, we recall the entire batch. In situations that do not qualify as quality deviations, we provide reports to customers and arrange for reimbursement.

* Controversial Ingredients: Our quality team is committed to ensuring the use of ingredients that are safe for the customer health and the environment. In 2024, we released a corporate policy to provide guidance on this matter at RD Saúde, which also includes the new list of controversial ingredients.

* Animal Welfare: We have an uncompromising commitment to not conduct animal testing, either on raw materials or finished products, so that suppliers must not hire or outsource tests to external laboratories. If efficacy or clinical tests are necessary, we opt for in vitro or in vivo methods, the latter conducted on volunteer humans. In both cases, we use laboratories approved by Anvisa, ensuring the integrity and ethics of the processes.

Supplier Governance

We believe in building honest, transparent, and responsible relationships with our suppliers and business partners. We have a leading role in strengthening our supply chain in a responsible manner through engagement, development, and joint development of solutions to ESG-related challenges. We recognize that the development of the supply chain is essential to our business and to the nation’s economy.

Supplier governance is based on four main pillars:

1. Full supply chain mapping
2. Risk monitoring and compliance
3. Partner engagement and development
4. Building strategic partnerships

For more efficient governance, we now categorize suppliers as follows:

* Private Labels
* Direct Suppliers
* Supplies Suppliers
* Special Suppliers

Our suppliers are further segmented in a matrix of relevance, based on the amount of business transactions with RD Saúde, the criticality of the sector, and the frequency of payments. Our management makes use of an algorithm system that is highly customizable to our monitoring needs, strictly observing the history of each supplier with clear criteria. This management approach enables efficiency in the analysis process for 100% of our supply chain.

We conduct risk assessments of our operations with suppliers, annually apply self-assessment questionnaires, and conduct on-site audits in suppliers of critical categories, monitoring their alignment with relevant legislation, People Code of ethics and conduct, and respect for human rights. Our Supplier Code of Ethics and Conduct has specific guidelines for this audience. All suppliers must sign a statement of acceptance and commitment to the content of this code. To ensure ongoing engagement with issues such as human rights, the environment, climate change, and others, we maintain active communication through regular newsletters.

Our governance and compliance system for suppliers, implemented in 2022, provides a comprehensive view of RD Saúde’s cycle of relationship with the supply chain. To achieve this, we go through the following steps:

* Homologation: Before being hired, all suppliers undergo homologation by the Supplier Governance team, which assesses their compliance and qualifications to meet the Company’s requirements and commitments, based on a list of required documents. In 2023, 1,692 new suppliers were homologated.

* Monitoring: Each supplier category has a specific monitoring process, in which we assess their practices and performance in relation to the themes relevant to our commitments. Suppliers included in critical categories, which present a higher risk of ESG non-conformity, are subjected to strict monitoring of social and environmental and compliance aspects, especially related to environmental licenses, debts and labor lawsuits. In 2023, we mapped 2,120 suppliers of critical categories.

Since 2022, we have been conducting on-site monitoring audits at tier 1 suppliers using our own team of auditors. This has enabled us to significantly expand the number of audited suppliers to 210, representing 9.9% of the 2,120 critical category suppliers. The selection of suppliers for auditing is established by prioritizing critical categories, such as RD Brands, suppliers of customized products, and construction companies involved in our projects. The audit results generate a supplier score from A to E and an action plan, regardless of the partner’s score. Monitoring cycles and implementation of improvements are established in accordance with the criticality of the occurrence.

Check out more details of our initiatives related to products and services in the GRI disclosures listed in this dashboard or in the Annual and Sustainability Report.

Related Policies

* Quality & Safety of Products & Services Policy
* Ingredient Safety Policy